Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.

By D. Selkoe, D. Schenk. Annual Review of Pharmacology and Toxicology, 2003

827 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Pharmacology, Physiology

View Paper: https://www.semanticscholar.org/paper/519ffc17c57e6843afb4610647d01ff7ce5f7919

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

1. L. Mucke
2. Christian Haass
3. Mark P. Mattson
4. C. Iadecola
5. J. Palop
6. D. Selkoe
7. P. Reddy

In Pharmacology

1. L. Mucke
2. J. Palop
3. Mark P. Mattson
4. Christian Haass
5. C. Iadecola
6. D. Selkoe
7. David Watson
8. P. Reddy

In Physiology

1. L. Mucke
2. J. Palop
3. D. Selkoe
4. Mark P. Mattson
5. Christian Haass
6. C. Iadecola
7. Jeannie Chin
8. Hélène Girouard

Citations in the corpus

• A network dysfunction perspective on neurodegenerative diseases (2006, background): “At present, diverse efforts are being directed at the elimination of the abnormal protein assemblies themselves, and with good reaso”
• Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. (2006, background): “Alzheimer disease (AD) is the most common form of dementia and is characterized by deposition of amyloid -peptide (A ) in the neuropil (neuritic plaques) and blood vessels (amyloid angiopathy), and by accumulation of hyperphosphorylated neurofilament in neurons (neurofibrillary tangles) (76).”
• ADAM10 is the physiologically relevant, constitutive α‐secretase of the amyloid precursor protein in primary neurons (2010, background): “Both proteolytic cleavages are central regulatory events in the generation of the amyloidb peptide (Ab), which has an important function in the pathogenesis of Alzheimer’s disease (AD) (Selkoe and Schenk, 2003; Haass, 2004).”
• Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology (2006, background): “These models have been instrumental in studying the impact and mechanism of cerebral amyloidosis and to develop therapeutic strategies (Selkoe & Schenk, 2003).”
• Pathways towards and away from Alzheimer's disease (2004, background): “The discoveries during the past 15 years of genetic aberrancies that either cause or increase the risk of AD heralded a rapid increase in knowledge of the molecular and cellular alterations responsible for neuronal degeneration and cognitive dysfunction in A”
• Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide (2007, background): “We will focus here on the neutralization of Aβ oligomers; refer to recent review”
• Voluntary Exercise Decreases Amyloid Load in a Transgenic Model of Alzheimer's Disease (2005, background): “Alzheimer’s disease (AD) is a progressive neurodegenerative disease that represents the eighth leading cause of death in people #65 years of age (Mayeux, 2003), affecting #20 –30 million people worldwide (Selkoe and Schenk, 2003).”